Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
NVDA -0.4EWJ 0.37TECK.B.TO -2.09CNQ.TO 0.71HHL.TO 0.075SYLD 0.03HAC.TO 0.04TRU -0.01
Teva Pharmaceutical (TEVA)

NYSE:TEVA

Teva Pharmaceutical (TEVA)

31.48
-0.00 (0.00%)
as of Jun 18, 2026, 10:41:24 pm Market Open.
46 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
DON'T BUY

Teva Pharmaceutical(TEVA)

Jan 05, 2024

It's cheap and has momentum, but that's all it has now. It never grabbed him.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad Money
No
Unlock Rating
$11.33

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
DON'T BUY

Teva Pharmaceutical(TEVA)

Aug 04, 2023

Massive share price appreciation not sustainable. 
Large debt load presents difficulties.
Does not own shares.
Would not recommend buying at this time. 

Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$9.75

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Teva Pharmaceutical(TEVA)

Jan 06, 2023
Has owned company for a long period of time in the past. Previous reasons for owning stock not present anymore. Waiting to see if new drugs are invented/patented.
Photo of David FingoldDavid FingoldUnlock Rating
$10.52

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA)

Mar 17, 2022
He's put the white flag up on this one. It's about macro interest rates, currency moves. Don't waste your time with these story stocks. His model price is $18.80, and it could have all the fundamentals, but the macro waves swamp the boat. Go with the big names.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$7.81

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA)

Nov 11, 2021
Tends to avoid companies with a ton of debt. Management missteps, and investors are paying for those. In the depths of a tough turnaround. He'd rather own a VTRS, where the debt is manageable, balance sheet's in better shape, with a better growth trajectory.
Photo of Lorne SteinbergLorne Steinberg
No
Unlock Rating
$9.55

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA)

Apr 15, 2021
Involved in the opiate crisis. Balance sheet is weak. Overall topline growth is low. Stay away. A lot of problems still to overcome.
Photo of Christine PooleChristine Poole
No
Unlock Rating
$10.85

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA)

Oct 19, 2020

Doesn't offer growth. The stock is weak and will stay weak.

Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$9.29

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
BUY

Teva Pharmaceutical(TEVA)

Feb 27, 2020
It's time to get back in. They all went crazy and then slid on sympathy when valiant went bust. There is tremendous value here. His model price is $21.26 or 63% upside. They presented earnings and the balance sheet looks great.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$12.21

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
HOLD

Teva Pharmaceutical(TEVA)

Nov 28, 2019
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
Photo of Bruce MurrayBruce Murray
No
Unlock Rating
$10.45

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA)

Aug 15, 2019
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
Photo of Lorne SteinbergLorne Steinberg
No
Unlock Rating
$6.16

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA)

Jul 17, 2019
He sold it at a 50% loss due to price declines in generic drugs. That deflation has decreased lately, which is sort of good news. One of their big drugs came off patent, too.
Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$8.11

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA)

Jul 03, 2019
A generic drug company that has had troubled times as pricing is becoming very competitive. Buyers are consolidating and squeezing margins. They have a MS drug that was a market leader, but now there are others competing. He would rather own brand name drug companies that can become leaders in their field.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$9.60

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA)

Jul 02, 2019
It has done very well. But they made a huge acquisitions three years ago, taking on a lot of debt. They went through several CEOs. The generic drug space is tough and competitive. Generic drug pricing is limited as we head towards a U.S. election; generics are a target of politicians. Also, there are many lawsuits in the generic drug industry. Generics should do better after the election.
Photo of Paul Harris, CFAPaul Harris, CFAUnlock Rating
$9.43

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Teva Pharmaceutical(TEVA)

May 22, 2019
He is more content owning the major pharma versus generic producers. The competition in the space too intense. They have been involved in the manufacturing of opiod based drugs, which could come under regulatory pressure.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$11.54

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Teva Pharmaceutical(TEVA)

May 03, 2019
There is hope for it. Good news is the generic price declines have subsided, but "less declines" is not where he wants to be right now. Challenged in the next 12-18 months. Could go to low 20s, but structural headwinds for the business.
Photo of Paul MacDonaldPaul MacDonald
No
Unlock Rating
$15.18

Stock price when the opinion was issued

$31.48

As of Jun 18, 2026. Market Open.

biotechnologypharmaceutical
Showing 1 to 15 of 272 entries

Teva Pharmaceutical (TEVA) Frequently Asked Questions

What is Teva Pharmaceutical stock symbol?

Teva Pharmaceutical is a American stock, trading under the symbol TEVA (previously TEVA-N on Stockchase) on the New York Stock Exchange (TEVA). It is usually referred to as NYSE:TEVA or TEVA

Is Teva Pharmaceutical a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on TEVA (previously TEVA-N on Stockchase) on Stockchase. Read the latest expert commentary for Teva Pharmaceutical.

Is Teva Pharmaceutical a good investment or a top pick?

Teva Pharmaceutical was recommended as a Top Pick by Paul MacDonald on 2019-05-03. Read the latest stock experts ratings for Teva Pharmaceutical.

Why is Teva Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Teva Pharmaceutical.

Is Teva Pharmaceutical worth watching?

Teva Pharmaceutical is followed by 46 investors on Stockchase and is a trending stock that is worth watching.

What is Teva Pharmaceutical stock price?

On 2026-06-18, Teva Pharmaceutical (TEVA) stock closed at a price of $31.48.

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

VEEV 0$153.3
WSP.TO 1.13$176.7
VRTX 0.47$452.1
OTEX.TO 0.24$29.47
CCO.TO 0.61$151.07

Today's Top Picks

NVDA -0.4$210.29
EWJ 0.37$96.63
TECK.B.T… -2.09$88.93
CNQ.TO 0.71$58.66
HHL.TO 0.075$6.865

Popular Articles

Latest Sell Signals

TD.TO 0.7$169.33
MBLY -0.03$8.43
ASAN 0.03$6.95
MODG -0.01$18.21
NVTS 0$24.02

Most Recent Experts

Stockchase Insights

Stockchase Insights

5i Research

Brian Acker, CA

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica